The Center for Biosimilars recaps the the top 5 articles for the week of December 18, 2017.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 18.
Number 5: A newly published study shows that adalimumab is effective in treating stricturing Crohn disease.
Number 4: Mylan announced that the US Patent Trial and Appeal Board has instituted inter partes review proceedings on all claims against 2 patents covering Sanofi’s Lantus.
Number 3: Tax disclosures show that industry group PhRMA spent millions on lobbyists, politicians, and patient groups in 2016.
Number 2: Attorney Kevin Nelson, partner at Schiff Hardin, explained the impact that the federal circuit’s ruling in Amgen v Sandoz will have on biosimilar developers.
Number 1: The FDA has accepted for review Samsung Bioepis’ Biologics License Application for SB3, a proposed trastuzumab biosimilar.
Finally, last week, our e-newsletter asked whether you think that the FDA has become more lenient in approving drugs under current leadership. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.